S100蛋白质作为多关节性青少年异常性关节炎中阿巴cept反应的潜在预测生物标志物

相关实验视频

Updated: Jun 23, 2025

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

572

Hermine I Brunner1, Grant S Schulert2, Alyssa Sproles2

  • 1Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Hermine.brunner@cchmc.org.

Arthritis research & therapy
|June 25, 2024
PubMed
概括

较低的S100A8/9和S100A12蛋白质水平预测了多关节性青少年异常性关节炎 (pJIA) 治疗阿巴切的更好反应. 这些生物标志物可能有助于指导pJIA患者的治疗决策.

关键词:
这就是Abatacept.生物标志物 生物标志物在C-反应蛋白 (CRP) 中.青少年无形性关节炎 (Juvenile idiopathic arthritis) 是一种不良的疾病.在S100中,S100就是S100.

更多相关视频

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

418
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

相关概念视频

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130